Using a machine learning software platform (AMPLY) to solve the global animal health problem of Bovine Mastitis through use of novel, patentable, antimicrobial peptides

AMPERT是贝尔法斯特女王大学的一个抗菌产品发现分支机构，它采用创新的机器学习和人工智能方法来挖掘庞大的生物数据集，寻找新的生物活性肽。AMBERNIA专注于动物健康市场，寻找影响畜牧业和全球食物链的复杂疾病的答案。该项目验证了使用AMBERNIA技术开采的候选抗菌肽，这些抗菌肽有可能解决牛乳腺炎（BM）这一全球性问题，这是一种由于细菌感染引起的奶牛乳房组织的持续炎症反应。根据英国农业和园艺发展委员会的说法，“乳房炎的治疗和控制是英国乳制品行业最大的成本之一，也是奶牛福利的重要因素”。BM影响牛奶产量和质量。预计到2023年，该市场将达到14.4亿美元。据估计，全球BM的医疗保健负担可能为每年300亿美元。目前BM治疗中出现的一个必然问题是抗生素耐药性的影响，这是全球十大公共卫生威胁。AMPERT正在使用人工智能更快地生产新的候选药物，降低药物开发风险，并为畜牧业创造解决方案，同时保护人类的食物链。

AMPLY is an antimicrobial product discovery spin-out from the Queen's University of Belfast which employs innovative machine learning and AI methods to mine huge biological datasets searching for novel bioactive peptides. AMPLY focuses on the animal health market searching for answers to complex diseases which affect the livestock industry and the global food chain.This project validates candidate antimicrobial peptides, mined using AMPLY's technology, which have the potential to solve the global problem of Bovine Mastitis (BM), a persistent, inflammatory reaction of a cow's udder tissue due to bacterial infection. According to the Agriculture and Horticulture Development Board, UK "_Mastitis treatment and control is one of the largest costs to the GB dairy industry and is a significant factor in dairy cow welfare_". BM impacts milk production and quality. The market is predicted to reach $1.44 billion by 2023\.Estimates show healthcare burden globally of BM may be $30 billion annually. A corollary issue arising from current treatments for BM is the impact of antimicrobial resistance, a top 10 global public health threat.AMPLY is using AI to produce new drug candidates more quickly, de-risking drug development, and creating solutions for the livestock industry while safeguarding humanity's food chain.